Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients

Fatigue is one of the most prevalent symptoms endorsed by cancer survivors, particularly
those treated for breast cancer or Hodgkin lymphoma. Despite the tremendous implications
such work has for effective interventions, little is known about the underlying
pathophysiology of fatigue, association with medical co-morbidities and factors that may
help predict those to be at highest risk.

The proposed research will utilize Vanderbilt-Ingram Cancer Center REACH for Survivorship
Program together with the investigators Hematologic Malignancies Program. In adolescent and
young adults (AYA), ages 18 - 39 the investigators will address the following:

Primary Aims Aim 1: Assess the prevalence and severity of fatigue and its impact on
functional outcomes Aim 2: Determine host, disease and treatment-related risk factors for
fatigue

Secondary Aims Aim 1: Evaluate the association between levels of proinflammatory cytokine
activity and fatigue Aim 2: Evaluate the association between fatigue and self reported
fatigue in AYA Hodgkin lymphoma (HL) survivors.

Hypotheses:

1. Fatigue is more prevalent and severe among AYA HL patients and survivors, compared to
general population and will be associated with impaired functional outcome.

2. Risk factors for fatigue include higher disease stage, B symptoms and elevated
erythrocyte sedimentation rate at diagnosis, dose density of chemotherapy and higher
doses and more expanded fields of radiotherapy.

3. Risk of fatigue is associated with long-term cardiopulmonary and endocrine
complications.

4. Levels of specified proinflammatory cytokines are associated with increased fatigue.